您的购物车当前为空
OBA-09 is a novel multimodal neuroprotectant oxopropanoyloxy benzoic acid. OBA-09 displays robust protective effects in the postischemic brain.


为众多的药物研发团队赋能,
让新药发现更简单!
OBA-09 is a novel multimodal neuroprotectant oxopropanoyloxy benzoic acid. OBA-09 displays robust protective effects in the postischemic brain.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 198 | 现货 | |
| 5 mg | ¥ 469 | 现货 | |
| 10 mg | ¥ 795 | 现货 | |
| 25 mg | ¥ 1,330 | 现货 | |
| 50 mg | ¥ 1,970 | 现货 | |
| 100 mg | ¥ 2,930 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 518 | 现货 |
| 产品描述 | OBA-09 is a novel multimodal neuroprotectant oxopropanoyloxy benzoic acid. OBA-09 displays robust protective effects in the postischemic brain. |
| 体外活性 | OBA-09 exhibited antioxidative effects in the postischemic brain, which was evidenced by the remarkable reduction of lipid peroxidation and 4-hydroxy-2-nonenal staining in OBA-09-administered animals. OBA-09 was capable of scavenging hydroxyl radical in cell-free assays. High-performance liquid chromatography results demonstrated that OBA-09 was hydrolyzed to salicylic acid and pyruvate with t1/2 = 43 min in serum and 4.2 h in brain parenchyma, indicating that antioxidative function of OBA-09 is executed by itself and also by salicylic acid after the hydrolysis. In addition to antioxidative function, OBA-09 exerts anti-excitotoxic and anti-Zn2+-toxic functions, which might be attributed to attenuation of ATP and nicotinamide adenine dinucleotide depletion and to the suppression of nuclear factor-κB activity induction. Together these results indicate that OBA-09 has a potent therapeutic potential as a multimodal neuroprotectant in the postischemic brain and these effects were conferred by OBA-09 itself and subsequently its hydrolyzed products. |
| 分子量 | 208.17 |
| 分子式 | C10H8O5 |
| CAS No. | 856095-68-6 |
| Smiles | CC(=O)C(=O)Oc1ccccc1C(O)=O |
| 密度 | no data available |
| 颜色 | Gray |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (480.38 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (15.85 mM), Sonication is recommeded. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多